Targeted extracellular vesicles for delivery of therapeutics
AssigneeMercury Bio, Inc.
InventorsRichard Sayre, Tatiana Vinogradova-Shah, Alexander Pertzev
Life of this patent
Estimating the term…
Abstract
The present invention is directed to Saccharomyces-generated extracellular vesicles (EVs) comprising a foreign RNA molecule or protein and at least one foreign membrane surface exposed ligand that specifically binds to a target receptor displayed on a target cell. The present invention also relates to methods of making and using these Saccharomyces-generated EVs for targeted gene silencing. The present invention also relates to fusion proteins comprising a Saccharomyces extracellular vesicle anchor protein and a second peptide designed to bind to cell-specific receptors.
Claims16
A pharmaceutical composition for the treatment of SARS-COV-2, comprising a quantity of extracellular vesicles (EVs) containing a heterologous ribonucleic acid (RNA) molecules directed to inhibit the expression of a SARS-CoV-2 gene, and a pharmaceutically acceptable carrier, wherein the EVs are generated from Saccharomyces boulardii.
A pharmaceutical composition comprising:
- a quantity of extracellular vesicle (EVs) containing a heterologous RNA directed to inhibit the expression of a pathogen gene, or an endogenous gene of a target cell, and a pharmaceutically acceptable carrier, wherein the EVs are generated from Saccharomyces boulardii.
A extracellular vesicle (EV) comprising a heterologous RNA molecule and optionally at least one heterologous membrane surface ligand that binds to a target surface molecule displayed on a target cell, wherein the at least one heterologous membrane surface ligand is linked to an anchor protein embedded in the lipid bilayer of the EV, and wherein the EV is generated from Saccharomyces boulardii.
Dependencies are inferred from the claim text.